Mylan, Biocon secure FDA nod for first biosimilar to cancer drug Neulasta

04:16 EDT 5 Jun 2018 | Pharmaceutical Business Review

Mylan and Biocon have secured approval from the US Food and Drug Administration for Fulphila (pegfilgrastim-jmbd), a biosimilar to Amgen’s cancer drug Neulasta (pegfilgrastim).

More From BioPortfolio on "Mylan, Biocon secure FDA nod for first biosimilar to cancer drug Neulasta"